EBOS Group Limited (ASX: EBO) has had a reliable operating year and managed to grow strongly. Despite challenging market conditions, the company’s revenue growth was 12% reaching $12,267 million in FY25, and that was without the CWA contract.
Underlying EBITDA grew to $585 million, representing a 7.5% growth compared to the previous year. Statutory EBITDA was $556 million, which is an 8.3% decrease, while statutory NPAT dropped by 19.8% to $274 million. Underlying EPS was 131.3 cpc, while statutory EPS was 109.7 cpc, which is a 22.4% decrease. The total dividend for the year was NZD 118.5 cents per share, which is the same as for FY24.
EBOS’s performance is a clear sign of the healthcare and animal-care divisions’ resilience. The company not only expanded its market share but also took a disciplined approach to investments in Australia, New Zealand, and Southeast Asia.
Why Did EBOS Deliver Solid FY25 Results?
The strong EBOS Group financial performance in 2025 was mainly the result of its diverse portfolio and the implementation of its strategy at the same time. EBOS reached several important goals, one of which was the opening of the Kemps Creek distribution centre.
This distribution centre is part of its multi-year $360 million renewal program. Further funds were invested in the animal health and medical technology sectors. The company’s cost-control measures and efficient transport system played a major role in securing profits during inflationary and regulatory periods, which was a challenge for many businesses.
The retail pharmacy network of the group, consisting of TerryWhite Chemmart, which opened 34 net new stores, and the group’s leadership in pharmacy distribution, were significant factors in the increase in sales of the company.
How Does the EBOS Group FY26 Outlook Look?
The EBOS Group FY26 outlook keeps its confidence but remains careful. The business is predicted to achieve Group EBITDA before one-off items amounting to $615 million to $635 million, which is in the middle of the range, about a 7% increase. The management gives the second half of FY26 assessment as strong since its infrastructure projects will be operating at full capacity by then.
EBOS also reiterated significant strides made in regard to the Perth Contract Logistics Distribution Centre and the completion of its eight-site DC rejuvenation program. The company is also planning an investor day for the fourth quarter of FY26 in order to present its long-term growth strategy.
EBOS delivering consistent earnings and growth
EBOS Group Strengthens Strategic Priorities
EBOS still places most importance on operational excellence, supply chain resilience and market diversification. The EBOS Group FY25 results are a testament to the company’s ability to produce steady profits and maintain shareholders’ value. A good financial position, along with the continuous investment in technology and infrastructure, makes EBOS ready to propel its growth beyond the fiscal year 2026.
Moreover, the company pointed out its sustainable development projects and its dedication to doing creative things in healthcare logistics and animal health. These elements are the main ones in the company’s long-range plan, and they also give the company a very strong basis for further growth.
What Challenges Impact EBOS Group’s FY26 Path?
As EBOS transitions into fiscal year 2026, a number of adverse factors are already visible. Margins are likely to be adversely impacted by the persistently weak demand for pet-nutrition products and the continued pressure on global supply chains. On the other hand, the government-sponsored projects, for example, in the case of the S$4.2 billion five-year Pharmacy Wholesaler Agreement in Australia, should cover, at least partially, the negatives.
The very fact that the company has diverse operations in the fields of health care, animal care and medical technology contributes to its stability. Further, the implementation of automation and advanced warehousing capabilities should not only cut costs but also increase the company’s capacity and the rate of production.
EBOS expanding its logistics footprint
Why Is FY26 a Transition Year For EBOS Group?
FY26 is the transition year when EBOS will finally reap the rewards of the prominent infrastructure investments, and it is thus going to be a significant year for the company. The new distribution centres and improved systems are expected to be the main contributors to the company’s revenue growth starting from FY27 onwards. The main goal of the company is to expand its production and operational capacity while still applying controls on costs due to inflation.
EBOS management has once again confirmed its promise to sustain growth through careful spending and strategic acquisitions. The company, being one of the largest distributors in the healthcare and animal care segments in Australasia, is in a very good position to take over its rivals.
Also Read: EBOS Unveils High-Tech Western Sydney Warehouse to Revolutionise Australia’s Supply Chain Efficiency
FAQs
Q1: What were the most important elements of the EBOS Group FY25 results?
The company was able to increase its revenue by 12%, amounting to $12,267 million, the underlying EBITDA was up by 7.5% to $585 million, and the same NZ 118.5 cents per share dividend was declared.
Q2: What is EBOS Group’s FY26 outlook projecting?
The management expects the underlying Group EBITDA to be in the range of $615 million and $635 million, indicating that the company is going to keep the growth momentum.
Q3: Why is FY26 considered to be a transition year?
EBOS is in the process of building up its distribution infrastructure and is making major investments, while the company is going to reap the benefits from FY27.
Q4: What factors can be relied upon to maintain EBOS’s performance in the future?
The company’s strong market position, varied sources of income, and technological investments are the main contributors to the company’s upward growth path.
